Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antipsychotic medication |
| gptkbp:approvalYear |
September 2015
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States 2015 (US) 2017 (EU) |
| gptkbp:ATCCode |
N05AX15
|
| gptkbp:blackBoxWarning |
suicidal thoughts and behaviors
increased mortality in elderly patients with dementia-related psychosis |
| gptkbp:brand |
Reagila
Vraylar |
| gptkbp:CASNumber |
846589-98-8
|
| gptkbp:chemicalFormula |
C21H32Cl2N4O
|
| gptkbp:contraindication |
hypersensitivity to cariprazine
|
| gptkbp:developedBy |
gptkb:Gedeon_Richter
gptkb:Allergan |
| gptkbp:drugClass |
antipsychotic medication
|
| gptkbp:eliminationHalfLife |
2–4 days (cariprazine)
1–3 weeks (active metabolites) |
| gptkbp:form |
capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
cariprazine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
serotonin 5-HT2A receptor antagonist
serotonin 5-HT1A receptor partial agonist dopamine D2 receptor partial agonist dopamine D3 receptor partial agonist |
| gptkbp:metabolism |
gptkb:CYP3A4
CYP2D6 (minor) |
| gptkbp:molecularWeight |
426.41 g/mol
|
| gptkbp:notRecommendedFor |
pediatric patients
|
| gptkbp:patentExpired |
2028 (US)
|
| gptkbp:pregnancyCategory |
Not assigned
|
| gptkbp:pregnancyWarning |
may cause extrapyramidal and/or withdrawal symptoms in neonates
|
| gptkbp:prescribes |
adults
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
anxiety dizziness weight gain restlessness insomnia extrapyramidal symptoms akathisia |
| gptkbp:synonym |
MP-214
RGH-188 |
| gptkbp:usedFor |
gptkb:bipolar_I_disorder
bipolar disorder schizophrenia bipolar mania bipolar depression major depressive disorder (adjunct) |
| gptkbp:bfsParent |
gptkb:N05AX
gptkb:Dopamine_D3_Receptor gptkb:5-HT2C_receptor |
| gptkbp:bfsLayer |
7
|